https://www.nasdaq.com/press-release/alx-oncology-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01
https://www.nasdaq.com/press-release/durect-corporation-expands-board-of-directors-with-appointment-of-biopharmaceutical
https://www.nasdaq.com/press-release/alx-oncology-announces-initial-data-from-aspen-02-the-ongoing-phase-1-2-study-of
https://www.nasdaq.com/press-release/alx-oncology-reports-third-quarter-2021-financial-results-and-provides-clinical
https://www.nasdaq.com/press-release/alx-oncology-announces-updated-data-from-ongoing-clinical-trial-aspen-01-of
https://www.nasdaq.com/press-release/alx-oncology-to-present-new-evorpacept-clinical-data-in-myelodysplastic-syndromes-at
https://www.nasdaq.com/press-release/alx-oncology-announces-upcoming-virtual-investor-conference-participation-2021-11-02
https://www.nasdaq.com/press-release/alx-oncology-announces-first-patient-dosed-in-aspen-05-a-phase-1-2-study-of
https://www.nasdaq.com/press-release/alx-oncology-strengthens-immuno-oncology-pipeline-with-acquisition-of-scalmibio-2021
https://www.nasdaq.com/press-release/zymeworks-and-alx-oncology-announce-first-patient-dosed-in-phase-1b-2-clinical-trial
https://www.nasdaq.com/press-release/alx-oncology-announces-four-abstracts-accepted-for-presentation-at-the-society-for
https://www.nasdaq.com/press-release/alx-oncology-announces-initiation-of-investigator-sponsored-trial-of-evorpacept
https://www.nasdaq.com/press-release/lightstone-ventures-raises-%24375-million-fund-2021-09-14
https://www.nasdaq.com/press-release/alx-oncology-announces-upcoming-virtual-investor-conference-participation-2021-09-07
https://www.nasdaq.com/press-release/alx-oncology-reports-second-quarter-2021-financial-results-and-provides-clinical
https://www.nasdaq.com/press-release/alx-oncology-announces-first-patient-dosed-in-aspen-04-a-phase-2-study-of-alx148-in
https://www.nasdaq.com/press-release/alx-oncology-announces-new-data-from-aspen-01-the-phase-1b-study-of-alx148-showing-0
https://www.nasdaq.com/press-release/alx-oncology-announces-update-on-aspen-03-and-aspen-04-the-alx148-phase-2-head-and
https://www.nasdaq.com/press-release/alx-oncology-to-collaborate-with-lilly-to-evaluate-alx148-plus-cyramzar-ramucirumab
https://www.nasdaq.com/press-release/alx-oncology-announces-upcoming-virtual-investor-conference-participation-2021-05-18
https://www.nasdaq.com/press-release/alx-oncology-reports-first-quarter-2021-financial-results-and-provides-clinical
https://www.nasdaq.com/press-release/alx-oncology-announces-first-patient-dosed-in-aspen-03-a-phase-2-study-of-alx148-in
https://www.nasdaq.com/press-release/alx-oncology-to-present-alx148-clinical-data-at-the-esmo-23rd-world-congress-on
https://www.nasdaq.com/press-release/alx-oncology-strengthens-ip-portfolio-announces-end-of-post-grant-review-period-for
https://www.nasdaq.com/press-release/alx-oncology-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/alx-oncology-announces-appointment-of-sophia-randolph-m.d.-ph.d.-to-board-of
https://www.nasdaq.com/press-release/alx-oncology-and-tallac-therapeutics-announce-collaboration-on-novel-class-of-cancer
https://www.nasdaq.com/press-release/alx-oncology-to-participate-at-h.c.-wainwright-global-life-sciences-conference-2021
https://www.nasdaq.com/press-release/alx-oncology-provides-corporate-update-and-highlights-key-milestones-in-2021-2021-01
https://www.nasdaq.com/press-release/alx-oncology-to-present-at-39th-annual-j.p.-morgan-healthcare-conference-2021-01-05
https://www.nasdaq.com/press-release/alx-oncology-added-to-the-nasdaq-biotechnology-index-2020-12-17
https://www.nasdaq.com/press-release/alx-oncology-announces-closing-of-public-offering-and-full-exercise-of-the
https://www.nasdaq.com/press-release/alx-oncology-announces-pricing-of-upsized-public-offering-of-common-stock-2020-12-09
https://www.nasdaq.com/press-release/alx-oncology-announces-proposed-public-offering-of-common-stock-2020-12-07
https://www.nasdaq.com/press-release/alx-oncology-announces-updated-data-from-aspen-01-the-ongoing-phase-1b-study-of
https://www.nasdaq.com/press-release/alx-oncology-announces-updates-on-planned-alx148-phase-2-head-and-neck-cancer-studies
https://www.nasdaq.com/press-release/alx-oncology-announces-december-2020-virtual-investor-conference-participation-2020
https://www.nasdaq.com/press-release/zymeworks-and-alx-oncology-announce-clinical-collaboration-evaluating-zanidatamab
https://www.nasdaq.com/press-release/alx-oncology-reports-third-quarter-2020-financial-results-and-provides-clinical
https://www.nasdaq.com/press-release/alx-oncology-announces-new-data-from-aspen-01-the-phase-1b-study-of-alx148-showing
https://www.nasdaq.com/press-release/alx-oncology-to-present-alx148-clinical-data-at-the-62nd-american-society-of
https://www.nasdaq.com/press-release/alx-oncology-announces-november-2020-virtual-investor-conference-participation-2020
https://www.nasdaq.com/press-release/alx-oncology-announces-first-patient-dosed-in-aspen-02-a-phase-1-2-study-of-alx148-in
https://www.nasdaq.com/press-release/alx-oncology-to-present-alx148-clinical-data-at-the-society-for-immunotherapy-of
https://www.nasdaq.com/press-release/alx-oncology-names-leading-oncology-experts-to-scientific-advisory-board-2020-10-06
https://www.nasdaq.com/press-release/alx-oncology-to-collaborate-with-merck-on-phase-2-immuno-oncology-studies-evaluating
https://www.nasdaq.com/press-release/alx-oncology-added-to-russell-2000r-and-3000r-indexes-2020-09-17
https://www.nasdaq.com/press-release/alx-oncology-announces-participation-at-upcoming-investor-conferences-2020-09-08
